Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kiniksa Pharmaceuticals Ltd.

www.kiniksa.com

Latest From Kiniksa Pharmaceuticals Ltd.

Keeping Track: Submissions From Alkermes, Samsung Bioepis; BTDs for Orphazyme and Kiniksa

The latest submission and expedited review program news and highlights from our US FDA Performance Tracker.

US FDA Performance Tracker Drug Review

Galderma’s First-In-Class Biologic Chases Eczema Spoils

Galderma’s novel biologic is heading for Phase III studies in moderate-to-severe atopic dermatitis as the race to join Dupixent in an expanding market hots up.

Clinical Trials Dermatology

Finance Watch: Gossamer, Alector And Harpoon Launch First Biopharma IPOs Of 2019

Public Company Edition: Grossing $276m, Gossamer would have been the third-largest biopharma IPO in the US if it had launched last year. Also, recent public company financings include debt and follow-on offerings; and two more firms cut jobs – Capricor and Seres.

Financing Business Strategies

Start-Up Quarterly Statistics: A Record-Breaking Q2 As Financings Surge

Biopharma start-ups had a record-breading quarter in terms of fundraising. A review of biopharma start-up deal-making and financing activity from April through June 2018, based on data from Strategic Transactions.

Financing StartUps and SMEs
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Dermatology
  • Immune Disorders
  • Inflammation
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Kiniksa Pharmaceuticals Ltd.
  • Senior Management
  • Sanj Patel, CEO
    Chris Heberlig, CFO
    Stephen Mahoney, Pres. & COO
    John Paolini, MD, PhD, CMO
    Eben Tessari, CBO
  • Contact Info
  • Kiniksa Pharmaceuticals Ltd.
    Phone: (781) 431-9100
    100 Hayden Ave.
    Lexington, MA 02421
    USA
UsernamePublicRestriction

Register